Molecular Mechanisms of Neurodegenerative Diseases: Emerging Biomarkers and Therapeutic Targets
Brain Sciences · 27.06.2026 · 16 (7) · 675
DOI: 10.3390/brainsci16070675 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 27.06.2026. Verfasst von Sunanda Yogi und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biology, University of Dayton, Dayton, OH 45469, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 116 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, University of Dayton.
Abstract (Originalsprache)
Neurodegenerative diseases (NDs), such as Alzheimer’s disease (AD), Parkinson’s disease (PD), Amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD), involve the gradual loss of structure or function of neurons in the nervous system and are an increasing threat to the aging population worldwide. Although these disorders have different clinical features which affect cognition, movement and other vital body functions, they share key underlying molecular and cellular processes. This starts with protein misfolding and aggregation, mitochondrial dysfunction, oxidative stress, dysregulated protein homeostasis, neuroinflammation, and disrupted cell death pathways. Recent findings have added disease-specific processes, like amyloid-β and tau aggregates in AD, α-synuclein aggregation and mitophagy failure in PD’s, TDP-43-related impaired RNA metabolism in ALS, and mutant huntingtin causing transcription aberrations in HD. Protein interactome network analysis showed mechanistic crosstalk between pathogenic proteins of AD and PD. New evidence highlights how lysosomal dysfunction, endoplasmic reticulum stress, and microglial activation, act as a common axis in neurodegeneration. Advancements in genomics and epigenomics have found shared genetic risk loci and regulatory processes that affect how diseases develop and progress. Simultaneously, new biomarkers like circulating microRNAs, exosome-related pathological proteins, neurofilament light chain, inflammatory cytokines, and microglial activation markers are powering early diagnosis tools and disease variations. New imaging techniques also allow for the identification of protein aggregations before symptoms appear. Overall, these findings are accelerating targeted treatments and personalized medicine aimed at disease progression. This review highlights current insights into the molecular mechanisms of NDs and discusses new biomarkers and treatment targets that help future diagnostic and treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Biology, University of Dayton, Dayton, OH 45469, USA.
- Integrative Science and Engineering Center, University of Dayton, Dayton, OH 45469, USA.
- Center for Genomic Advocacy (TCGA), Indiana State University, Terre Haute, IN 47809, USA.
ORCID-Profile: Amit Singh
Förderung
- NEI NIH HHS
- University of Dayton
Zitieren
APA
Yogi, S., & Singh, A. (2026). Molecular Mechanisms of Neurodegenerative Diseases: Emerging Biomarkers and Therapeutic Targets. Brain Sciences, 16(7), 675. https://doi.org/10.3390/brainsci16070675
Vancouver
Yogi S, Singh A. Molecular Mechanisms of Neurodegenerative Diseases: Emerging Biomarkers and Therapeutic Targets. Brain Sciences. 2026;16(7):675. doi:10.3390/brainsci16070675
BibTeX
@article{Yogi2026,
author = {Yogi, Sunanda and Singh, Amit},
title = {Molecular Mechanisms of Neurodegenerative Diseases: Emerging Biomarkers and Therapeutic Targets},
journal = {Brain Sciences},
year = {2026},
volume = {16},
number = {7},
pages = {675},
doi = {10.3390/brainsci16070675}
}
EUVIMED